BIOCURE TECHNOLOGY INC. (1WH) - Net Assets
Based on the latest financial reports, BIOCURE TECHNOLOGY INC. (1WH) has net assets worth €1.58 Million EUR (≈ $1.84 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.01 Million ≈ $2.35 Million USD) and total liabilities (€435.01K ≈ $508.58K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BIOCURE TECHNOLOGY INC. (1WH) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.58 Million |
| % of Total Assets | 78.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 16.96 |
BIOCURE TECHNOLOGY INC. - Net Assets Trend (2021–2025)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s net assets have evolved over time, based on quarterly financial data. See 1WH defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BIOCURE TECHNOLOGY INC. (2021–2025)
The table below shows the annual net assets of BIOCURE TECHNOLOGY INC. from 2021 to 2025. For live valuation and market cap data, see BIOCURE TECHNOLOGY INC. market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.58 Million ≈ $1.84 Million |
+17.55% |
| 2024-12-31 | €1.34 Million ≈ $1.57 Million |
-16.37% |
| 2023-12-31 | €1.60 Million ≈ $1.87 Million |
+168.87% |
| 2022-12-31 | €-2.33 Million ≈ $-2.72 Million |
-173.11% |
| 2021-12-31 | €-852.32K ≈ $-996.45K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BIOCURE TECHNOLOGY INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 214602400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €25.51 Million | 1618.82% |
| Total Equity | €1.58 Million | 100.00% |
BIOCURE TECHNOLOGY INC. Competitors by Market Cap
The table below lists competitors of BIOCURE TECHNOLOGY INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rare Foods Australia Ltd
AU:RFA
|
$962.23K |
|
Severfield PLC
LSE:SFR
|
$962.85K |
|
Venture Life Group PLC
LSE:VLG
|
$963.49K |
|
International Frontier Resources Corporation
V:IFR
|
$964.26K |
|
Satis Group S.A.
WAR:STS
|
$960.66K |
|
Protagenic Therapeutics
NASDAQ:PTIX
|
$959.41K |
|
Intercede Group
LSE:IGP
|
$958.93K |
|
Tearlach Resources Ltd
V:TEA
|
$958.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOCURE TECHNOLOGY INC.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,340,722 to 1,575,986, a change of 235,264 (17.5%).
- Net loss of 102,861 reduced equity.
- New share issuances of 100,000 increased equity.
- Other factors increased equity by 238,125.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-102.86K | -6.53% |
| Share Issuances | €100.00K | +6.35% |
| Other Changes | €238.12K | +15.11% |
| Total Change | €- | 17.55% |
Book Value vs Market Value Analysis
This analysis compares BIOCURE TECHNOLOGY INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-0.04 | €0.02 | x |
| 2022-12-31 | €-0.16 | €0.02 | x |
| 2023-12-31 | €0.15 | €0.02 | x |
| 2024-12-31 | €0.13 | €0.02 | x |
| 2025-12-31 | €0.08 | €0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOCURE TECHNOLOGY INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-6.53%) is above the historical average (-27.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.07 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.25 Million |
| 2023 | -113.13% | 0.00% | 0.00x | 1.23x | €-1.97 Million |
| 2024 | -19.58% | 0.00% | 0.00x | 1.49x | €-396.54K |
| 2025 | -6.53% | 0.00% | 0.00x | 1.28x | €-260.46K |
Industry Comparison
This section compares BIOCURE TECHNOLOGY INC.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,315,353,073
- Average return on equity (ROE) among peers: -93.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOCURE TECHNOLOGY INC. (1WH) | €1.58 Million | 0.00% | 0.28x | $960.84K |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $787.91 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $197.40 Million |
| PreveCeutical Medical Inc (18H) | $-344.34K | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $538.39 Million | -12.38% | 0.07x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.14 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $19.41 Billion | -3.43% | 0.16x | $20.05 Billion |
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more